Vector Science and Therapeutics (@VectorSciPAIN) header
Vector Science and Therapeutics (@VectorSciPAIN) profile picture

Precision therapeutics. Site-directed healing. Biomechanical devices + pharmaceutical-grade peptides. TSX Venture Exchange 🇨🇦 $PAIN.V

Joined July 2026
Photo by Vector Science and Therapeutics (@VectorSciPAIN)Photo by Vector Science and Therapeutics (@VectorSciPAIN)Photo by Vector Science and Therapeutics (@VectorSciPAIN)Photo by Vector Science and Therapeutics (@VectorSciPAIN)Photo by Vector Science and Therapeutics (@VectorSciPAIN)Photo by Vector Science and Therapeutics (@VectorSciPAIN)Photo by Vector Science and Therapeutics (@VectorSciPAIN)Photo by Vector Science and Therapeutics (@VectorSciPAIN)Photo by Vector Science and Therapeutics (@VectorSciPAIN)Photo by Vector Science and Therapeutics (@VectorSciPAIN)
🚨 **BIG WIN FOR PEPTIDE SCIENCE!** 🎉 The FDA's Pharmacy Compounding Advisory Committee has released its initial recommendations—and **6 peptides received favorable votes.** ✅ BPC-157 ✅ Epitalon ✅ KPV ✅ MOTS-c ✅ Semax ✅ TB-500 ❌ Emideltide (Delta Sleep-Inducing Peptide) This is a significant moment for the peptide industry and another sign that peptide therapeutics are gaining meaningful regulatory attention. While these recommendations are **preliminary and non-binding**, they're an exciting step toward the FDA's final guidance in the months ahead. At Vector Science & Therapeutics, we're excited about the future and remain focused on advancing **pharmaceutical-grade peptide manufacturing** and **next-generation targeted drug delivery technologies.** The momentum is real. 🚀 #Peptides #Biotech #RegenerativeMedicine #PrecisionMedicine #DrugDelivery #HealthcareInnovation #FDA #TSXV #PAIN
1
1
242
Big day for peptides. Yesterday, the FDA’s advisory committee voted in favor of allowing compounded BPC-157, KPV, and TB-500 to move one step closer to broader access through compounding pharmacies. Today, the committee continues reviewing additional peptides, including Semax, Epitalon, and DSIP (Emideltide). These are advisory votes—the FDA still makes the final decision—but this is a major shift worth watching. 👀🧬 At Vector, we’re committed to staying at the forefront of peptide science and keeping our community informed as this rapidly evolving field continues to unfold. Exciting times are ahead. 🚀 #Peptides #RegenerativeMedicine #Compounding #BPC157 #TB500 #KPV #Semax #Epitalon #DSIP #VectorScience
1
2
199
With 15 patent applications, we're creating new ways to deliver peptides, biologics, and other therapies more precisely—because better delivery has the potential to make treatments more effective and reduce unnecessary exposure to the rest of the body. Sometimes, the breakthrough isn't just the medicine. It's how you deliver it. #TSXV #PAIN.V #VectorScience #Biotech #Innovation
66
⚾ MLB All-Star Week is here July 10-14! For most athletes, being named an All-Star is a career milestone. In 2016, Dexter Fowler earned his first All-Star selection. But after working his way back from a hamstring injury, he made the difficult decision not to play because he knew his body wasn't ready. Sometimes the toughest call isn't pushing through. It's choosing recovery so you can keep playing the game you love. That perspective is one of the reasons Dexter now serves as Chief Athletic Officer of Valor by Vector. His mission is rooted in helping athletes think beyond one game, one season, or one moment—and focus on longevity, resilience, and what's possible when recovery becomes part of the performance. That's why Vector Science & Therapeutics is developing precision technologies designed to support tissue repair, recovery, and help athletes get back in the game, faster. Here's to all of this year's MLB All-Stars. 👏⚾ #MLBAllStar #ValorByVector #SportsMedicine #Recovery #Baseball $PAIN.V
1
48
Big news for Vector. We've secured an exclusive manufacturing agreement with LyoGenesis—a major step toward bringing our proprietary peptide technologies to physicians and clinics with pharmaceutical-grade quality. $PAIN.V
1
36
What if the problem isn't the peptide... What if it's the delivery? That's why Vector s focused on precision transdermal delivery—to help therapies reach the tissue they're intended to support. Because where a therapy goes matters. $PAIN.V
1
33
The lab has always had the answer. Valor makes sure the athlete hears it. For too long, elite athletes have been handed the same two options...push through the pain or shut it down completely. There’s a third option. And it starts in the lab. Valor is the sports medicine division of Vector Science & Therapeutics — built to connect elite athletes with clinically sound, non-addictive solutions for pain management and soft tissue repair. $PAIN.V | TSXV #ValorByVector #PAIN #FromTheLabToTheLockerRoom #SportsScience #AthleteRecovery
1
34
This isn’t a supplement. This is pharmaceutical-grade. Vector’s peptide formulations are manufactured at MPP Group LLC — FDA-registered, cGMP-compliant, 35,000 square feet of precision in Mequon, Wisconsin. $PAIN.V
1
50
Tommy Thompson — 19th U.S. Secretary of Health & Human Services, longest-serving Governor of Wisconsin in state history — has joined Vector Science & Therapeutics as Chairman of the Board.
29
One of the biggest regulatory decisions in the peptide industry is just weeks away. On July 23–24, the FDA's Pharmacy Compounding Advisory Committee will review seven peptides and recommend whether they should be eligible for pharmacy compounding.
31